Literature DB >> 24097557

Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes.

William R Hunt1, Susu M Zughaier, Dana E Guentert, Melissa A Shenep, Michael Koval, Nael A McCarty, Jason M Hansen.   

Abstract

Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity associated with cystic fibrosis (CF), impacting more than half of patients over age 30. CFRD is clinically significant, portending accelerated decline in lung function, more frequent pulmonary exacerbations, and increased mortality. Despite the profound morbidity associated with CFRD, little is known about the underlying CFRD-related pulmonary pathology. Our aim was to develop a murine model of CFRD to explore the hypothesis that elevated glucose in CFRD is associated with reduced lung bacterial clearance. A diabetic phenotype was induced in gut-corrected CF transmembrane conductance regulator (CFTR) knockout mice (CFKO) and their CFTR-expressing wild-type littermates (WT) utilizing streptozotocin. Mice were subsequently challenged with an intratracheal inoculation of Pseudomonas aeruginosa (PAO1) (75 μl of 1-5 × 10(6) cfu/ml) for 18 h. Bronchoalveolar lavage fluid was collected for glucose concentration and cell counts. A portion of the lung was homogenized and cultured as a measure of the remaining viable PAO1 inoculum. Diabetic mice had increased airway glucose compared with nondiabetic mice. The ability to clear bacteria from the lung was significantly reduced in diabetic WT mice and control CFKO mice. Critically, bacterial clearance by diabetic CFKO mice was significantly more diminished compared with nondiabetic CFKO mice, despite an even more robust recruitment of neutrophils to the airways. This finding that CFRD mice boast an exaggerated, but less effective, inflammatory cell response to intratracheal PAO1 challenge presents a novel and useful murine model to help identify therapeutic strategies that promote bacterial clearance in CFRD.

Entities:  

Keywords:  Pseudomonas; cystic fibrosis; cystic fibrosis-related diabetes; murine model; pneumonia

Mesh:

Year:  2013        PMID: 24097557      PMCID: PMC3920212          DOI: 10.1152/ajplung.00224.2013

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  46 in total

1.  Alterations of lung structure in experimental diabetes, and diabetes associated with hyperlipidaemia in hamsters.

Authors:  D Popov; M Simionescu
Journal:  Eur Respir J       Date:  1997-08       Impact factor: 16.671

2.  Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.

Authors:  Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Randall L Rosenblatt; Lynne Quittell; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2010-08-01       Impact factor: 21.405

3.  Alterations in granular (type II) pneumocyte ultrastructure by streptozotocin-induced diabetes in the rat.

Authors:  C G Plopper; W K Morishige
Journal:  Lab Invest       Date:  1978-02       Impact factor: 5.662

4.  The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis.

Authors:  Paulus Ripa; Ian Robertson; David Cowley; Margaret Harris; I Brent Masters; Andrew M Cotterill
Journal:  Clin Endocrinol (Oxf)       Date:  2002-03       Impact factor: 3.478

Review 5.  Diabetes mellitus in cystic fibrosis.

Authors:  D S Hardin; A Moran
Journal:  Endocrinol Metab Clin North Am       Date:  1999-12       Impact factor: 4.741

6.  Epidemiology of cystic fibrosis-related diabetes.

Authors:  B C Marshall; S M Butler; M Stoddard; A M Moran; T G Liou; W J Morgan
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

7.  Upregulation of caveolin-1 expression is associated with structural modifications of endothelial cells in diabetic lung.

Authors:  Elena Uyy; Felicia Antohe; Luminita Ivan; Raluca Haraba; Dorel Lucian Radu; Maya Simionescu
Journal:  Microvasc Res       Date:  2010-01-06       Impact factor: 3.514

8.  Subepithelial fibrosis and degradation of the bronchial extracellular matrix in cystic fibrosis.

Authors:  I Durieu; S Peyrol; D Gindre; G Bellon; D V Durand; Y Pacheco
Journal:  Am J Respir Crit Care Med       Date:  1998-08       Impact factor: 21.405

9.  Factors determining the appearance of glucose in upper and lower respiratory tract secretions.

Authors:  Barbara J Philips; Jean-Xavier Meguer; Jonathan Redman; Emma H Baker
Journal:  Intensive Care Med       Date:  2003-08-28       Impact factor: 17.440

10.  Aggresomes: a cellular response to misfolded proteins.

Authors:  J A Johnston; C L Ward; R R Kopito
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

View more
  19 in total

Review 1.  Mouse Modeling of Obese Lung Disease. Insights and Caveats.

Authors:  Benjamin T Suratt
Journal:  Am J Respir Cell Mol Biol       Date:  2016-08       Impact factor: 6.914

2.  Insulin signaling via the PI3-kinase/Akt pathway regulates airway glucose uptake and barrier function in a CFTR-dependent manner.

Authors:  Samuel A Molina; Hannah K Moriarty; Daniel T Infield; Barry R Imhoff; Rachel J Vance; Agnes H Kim; Jason M Hansen; William R Hunt; Michael Koval; Nael A McCarty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-02-17       Impact factor: 5.464

Review 3.  Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa.

Authors:  Rustin R Lovewell; Yash R Patankar; Brent Berwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-24       Impact factor: 5.464

4.  Hyperleptinemia is associated with impaired pulmonary host defense.

Authors:  Niki D J Ubags; Renee D Stapleton; Juanita H J Vernooy; Elianne Burg; Jenna Bement; Catherine M Hayes; Sebastian Ventrone; Lennart Zabeau; Jan Tavernier; Matthew E Poynter; Polly E Parsons; Anne E Dixon; Matthew J Wargo; Benjamin Littenberg; Emiel F M Wouters; Benjamin T Suratt
Journal:  JCI Insight       Date:  2016-06-02

5.  Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes.

Authors:  D H Limoli; J Yang; M K Khansaheb; B Helfman; L Peng; A A Stecenko; J B Goldberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-03-18       Impact factor: 3.267

Review 6.  Pancreatic pathophysiology in cystic fibrosis.

Authors:  Katherine N Gibson-Corley; David K Meyerholz; John F Engelhardt
Journal:  J Pathol       Date:  2015-10-01       Impact factor: 7.996

Review 7.  Cystic fibrosis related diabetes.

Authors:  Donal O'Shea; Jean O'Connell
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

8.  Sputum glucose and glycemic control in cystic fibrosis-related diabetes: a cross-sectional study.

Authors:  Lindsey Van Sambeek; Elise S Cowley; Dianne K Newman; Roberta Kato
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

9.  Differential Effect of LPS on Glucose, Lactate and Inflammatory Markers in the Lungs of Normal and Diabetic Mice.

Authors:  Cecilia Nagorny Holmberg; Annika Åstrand; Cecilia Wingren; James P Garnett; Gaëll Mayer; John D Taylor; Emma H Baker; Deborah L Baines
Journal:  J Pulm Respir Med       Date:  2017-05-11

10.  Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Michael Kreuter; Svenja Ehlers-Tenenbaum; Karin Palmowski; Jacques Bruhwyler; Ute Oltmanns; Thomas Muley; Claus Peter Heussel; Arne Warth; Martin Kolb; Felix J F Herth
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.